Last $0.52 USD
Change Today +0.0149 / 2.98%
Volume 6.2M
NSPH On Other Exchanges
NSPH is not on other exchanges.
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

nanosphere inc (NSPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/10/14 - $2.97
52 Week Low
10/22/14 - $0.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NANOSPHERE INC (NSPH)

Related News

No related news articles were found.

nanosphere inc (NSPH) Related Businessweek News

No Related Businessweek News Found

nanosphere inc (NSPH) Details

Nanosphere, Inc. provides molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment, and enhanced healthcare economics. Its Verigene System platform enables clinicians to identify and treat the bacteria and viruses for complex, costly, and deadly infectious diseases. The Verigene System includes a bench-top molecular diagnostics workstation for genomic and protein testing. The Verigene System is used for testing infectious disease assays, human and pharmacogenetic assays, and ultra-sensitive protein assays. The company focuses on serving hospital-based laboratories and academic research institutions in the United States. Nanosphere, Inc. was founded in 1998 and is headquartered in Northbrook, Illinois.

165 Employees
Last Reported Date: 02/18/14
Founded in 1998

nanosphere inc (NSPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $330.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $383.1K
Chief Strategy Officer
Total Annual Compensation: $211.0K
Compensation as of Fiscal Year 2013.

nanosphere inc (NSPH) Key Developments

Nanosphere Announces Unaudited Preliminary Sales Results for the Third Quarter Ended September 30, 2014

Nanosphere announced unaudited preliminary sales results for the third quarter ended September 30, 2014. Revenues for the third quarter 2014 were $3.7 million.

Nanosphere, Inc. Receives 510(K) Clearance from FDA on Verigene Enteric Pathogens Test

Nanosphere, Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Verigene(R) Enteric Pathogens Nucleic Acid Test (EP), which now includes additional viral targets, as well as the bacterial and toxigenic targets cleared by FDA earlier this summer. Verigene EP is a rapid, easy-to-use and cost-effective alternative to traditional stool diagnostics that the Company believes has the potential to deliver clinical, economic and workflow benefits to hospitals and laboratories. Verigene EP is Nanosphere's second FDA-cleared test in the area of gastroenteritis, joining the currently marketed Verigene Clostridium difficile Nucleic Acid Test (CDF), which identifies toxigenic C. difficile and differentiates the 027 hypervirulent strain for epidemiological purposes.

Nanosphere Receives Non-Compliance Notice From NASDAQ

On September 19, 2014, Nanosphere, Inc. received a deficiency letter from the Listing Qualifications Department of The NASDAQ Stock Market, notifying the Company that, for the last 30 consecutive business days, the closing bid price of the Company’s common stock has not been maintained at the minimum required closing bid price of at least $1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to Listing Rule 5450(a)(1) (“Minimum Bid Price Rule”). In accordance with NASDAQ Listing Rules, the Company has been given 180 calendar days, or until March 18, 2015, to regain compliance with the Minimum Bid Price. If at any time before March 18, 2015 the closing bid price of the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it complies with the Minimum Bid Price Rule. During this 180 calendar day period, the Company also may submit a plan to regain compliance to NASDAQ and may request up to an additional 180 calendar days to complete the plan. The Company is currently evaluating various alternative courses of action to regain compliance with the Minimum Bid Price Rule. However, there can be no assurance that the Company will regain compliance or maintain the listing of its common stock on the NASDAQ Global Market. If the Company does not regain compliance with the Minimum Bid Price Rule by March 18, 2015 or any extension period pursuant to a NASDAQ approved plan, the Staff will provide written notification to the Company that its common stock is subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Hearings Panel (the “Panel”). The Company would remain listed pending the Panel’s decision. There can be no assurance that, if the Company does appeal a delisting determination by the Staff to the Panel, such appeal would be successful.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSPH:US $0.52 USD +0.0149

NSPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GenMark Diagnostics Inc $9.66 USD +0.14
Great Basin Scientific Inc $5.36 USD -0.21
Meridian Bioscience Inc $17.97 USD +0.29
Quidel Corp $26.78 USD +0.58
Sequenom Inc $3.06 USD -0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation NSPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOSPHERE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at